Press Releases

and/or
565 News Releases found
Therapeutic Cloning Treats Parkinson's Disease in Mice

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Dr. Kenneth Offit, MD, MPH
At Home Genomic Tests for Disease Risk Premature

The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSKCC).
Chau Dang, MD
Media Advisory
Cardiac Effects Associated with Breast Cancer Treatment Appear Lower with Dose-Dense Delivery of Conventional Chemotherapy

A new pilot study by investigators at Memorial Sloan Kettering Cancer Center found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.
Kenneth Offit, MD, MPH
Researchers Identify New Genetic Marker for Breast Cancer

An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
Stephen D. Nimer, MD
Novel Mechanism Found That May Boost Impaired Function of Leukemia Protein

A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
Hans G. Lilja
PSA Testing Can Predict Advanced Prostate Cancer

A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan Kettering Cancer Center in New York and Lund University in Sweden.
Noah D. Kauff
Benefit of Cancer Prevention Surgery Differs Between Women with BRCA1 and BRCA2 Mutations

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either <I>BRCA1</I> or <I>BRCA2</I> mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center is the first prospective examination of the impact of this procedure in which <I>BRCA2</I> mutation carriers were analyzed separately from <I>BRCA1</I> mutation carriers.
Eric C. Holland
Simons Foundation Grant Boosts Brain Tumor Research

A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering's new Brain Tumor Center (BTC).
Joan Massagué
Molecules Can Block Breast Cancer's Ability to Spread

Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
Breast Cancer Risk Varies Substantially Among Women Who Are Carriers of BRCA1 and BRCA2 Gene Mutations

Breast cancer risk varies widely among women who are carriers of the <i>BRCA1</i> and <i>BRCA2</i> mutations, according to a new study published in the January 9, 2008, issue of the <i>Journal of the American Medical Association</i> (JAMA).